"Filgrastim" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Descriptor ID |
D000069585
|
MeSH Number(s) |
D12.644.276.374.410.240.350.500 D12.776.395.240.200.500 D12.776.467.374.410.240.350.500 D23.529.374.410.240.350.500
|
Concept/Terms |
Filgrastim- Filgrastim
- G-CSF Recombinant, Human Methionyl
- G CSF Recombinant, Human Methionyl
- Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor
- Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
- R-metHuG-CSF
- R metHuG CSF
Zarxio- Zarxio
- Filgrastim-Sandoz
- Filgrastim Sandoz
- FilgrastimSandoz
- Filgrastim-Sndz
- Filgrastim Sndz
|
Below are MeSH descriptors whose meaning is more general than "Filgrastim".
Below are MeSH descriptors whose meaning is more specific than "Filgrastim".
This graph shows the total number of publications written about "Filgrastim" by people in this website by year, and whether "Filgrastim" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 4 | 3 | 7 |
2018 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Filgrastim" by people in Profiles.
-
Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract. 2021 08; 17(8):e1235-e1245.
-
Post-COVID-19 severe neutropenia. Pediatr Blood Cancer. 2021 05; 68(5):e28866.
-
G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19? Acta Haematol. 2021; 144(4):355-359.
-
Personalized cancer supportive care in COVID-19 era. Ann Oncol. 2020 07; 31(7):835-837.
-
Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. Transfusion. 2018 05; 58(5):1143-1148.
-
Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients. Eur J Cancer. 2018 01; 89:49-55.
-
Automated red blood cell exchange in preparation for filgrastim mobilization of autologous peripheral blood hematopoietic progenitor cells in a patient with sickle cell anemia. J Clin Apher. 2018 Jun; 33(3):431-435.
-
Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study. Transfus Apher Sci. 2017 Dec; 56(6):832-835.
-
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
-
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018 01; 26(1):7-20.